HomeTOP STORIESSummit Therapeutics plans interim PFS analysis for HARMONi-3 squamous cohort in Q2... Summit Therapeutics plans interim PFS analysis for HARMONi-3 squamous cohort in Q2 2026 as clinical pipeline expands By rogerjudd February 24, 2026 FacebookTwitterPinterestWhatsApp Post Content Previous articleEuropean shares fall as tariff confusion returns, car sales dropNext articleI.R.S. Tactics Against Meta Open a New Front in the Corporate Tax Fight latest articles The inflation process has shifted even as headline CPI declined – Federal Reserve Cerrado Gold reports Q4 results As H-1B Visa Program Changes, Skilled Foreign Workers Consider Leaving U.S. They Get Drunk Without Drinking: What It’s Like to Have Auto-brewery Syndrome Parents Who Borrowed for Children’s College Face Looming Deadline Watch: Artemis II’s journey so far… in 85 seconds explore more The inflation process has shifted even as headline CPI declined – Federal Reserve Cerrado Gold reports Q4 results As H-1B Visa Program Changes, Skilled Foreign Workers Consider Leaving U.S. They Get Drunk Without Drinking: What It’s Like to Have Auto-brewery Syndrome Parents Who Borrowed for Children’s College Face Looming Deadline Watch: Artemis II’s journey so far… in 85 seconds
